Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study

Abstract

Background/Aim: Abdominal ultrasonography (USG) is recommended as a surveillance test for high-risk groups for hepatocellular carcinoma (HCC). This study aimed to analyze the current status of the national cancer surveillance program for HCC in South Korea and investigate the effects of patient-, physician-, and machine-related factors on HCC detection sensitivity.Methods: This multicenter retrospective cohort study collected surveillance USG data from the high-risk group for HCC (liver cirrhosis or chronic hepatitis B or C >40 years of age) at eight South Korean tertiary hospitals in 2017.Results: In 2017, 45 experienced hepatologists or radiologists performed 8,512 USG examinations. The physicians had a mean 15.0±8.3 years of experience; more hepatologists (61.4%) than radiologists (38.6%) participated. Each USG scan took a mean 12.2±3.4 minutes. The HCC detection rate by surveillance USG was 0.3% (n=23). Over 27 months of follow-up, an additional 135 patients (0.7%) developed new HCC. The patients were classified into three groups based on timing of HCC diagnosis since the 1st surveillance USG, and no significant intergroup difference in HCC characteristics was noted. HCC detection was significantly associated with patient-related factors, such as old age and advanced fibrosis, but not with physician- or machine-related factors.Conclusions: This is the first study of the current status of USG as a surveillance method for HCC at tertiary hospitals in South Korea. It is necessary to develop quality indicators and quality assessment procedures for USG to improve the detection rate of HCC.

The Epidemiology of Hepatitis B Virus Infection in Korea: 15-Year Analysis

“… 19 20 Therefore, despite the declining HBsAg positivity rate, it is imperative to maintain ongoing public health concerns and research pertaining to hepatitis B. 21 …”

Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels

“…Chronic hepatitis B (CHB) virus infection, affecting an alarming 296 million individuals as of 2019, stands as a primary cause of hepatic decompensation and hepatocellular carcinoma (HCC) [ 1 , 2 ]. With the advancements in antiviral therapies, particularly the advent of high potency nucleos(t)ide analogues (NAs) like entecavir and tenofovir, the risk of HCC has dramatically diminished, consequently bolstering the survival rates of CHB patients [ 3 ].…”